ArticleJournal of thoracic disease2025
Metastatic sites, prognosis, and a new nomogram for predicting overall survival among small cell lung cancer patients with liver metastasis: a retrospective study based on SEER.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A predictive model for immunotherapy in extensive-stage small cell lung cancer based on peripheral blood.Journal of thoracic disease · 2026Article
- Demographic and racial disparities in small-cell lung carcinoma: trends in diagnosis to treatment time, chemoradiotherapy seeking, and incidence rates-A SEER database analysis (2000-2021) with Bayesian multilevel regression modeling.Annals of medicine and surgery (2012) · 2025Article
- Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy.Translational lung cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC) is acknowledged as the most aggressive histological subtype among the various types of lung cancer. Among patients with advanced-stage SCLC, liver metastasis (LM) is frequently observed and is associated with the most unfavorable prognosis. The purpose of the present study is to investigate the synchronous metastatic sites in SCLC patients with LM, and to construct a nomogram for predicting the survival of these patients. Methods: The data of SCLC patients with LM in the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively analyzed. Univariate and multivariate Cox analyses were conducted to identify independent prognostic factors. A prognostic nomogram was developed and validated through calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA). There were 128 patients from the Jilin Cancer Hospital selected for external validation. The overall survival (OS) of patients with LM was estimated using the Kaplan-Meier method, and survival differences were compared using the log-rank test. Results: This study included a total of 8,858 patients, with independent prognostic factors for LM in SCLC patients being age, gender, primary site, surgery, radiotherapy, chemotherapy, brain metastasis, and lung metastasis. The calibration, ROC curves, and DCA collectively demonstrated the outstanding predictive accuracy of the prognostic nomogram. Bone was the most common accompanying organ for metastasis in SCLC-LM patients, followed by the lungs. Among the eight different groups based on metastatic patterns, compared to patients with isolated LM, those with concurrent metastases at other sites had a higher risk of death and poorer prognosis. Patients with LM accompanied by lung metastasis had the poorest prognosis, with a median survival time of 2 months. Conclusions: The nomogram is anticipated to serve as a precise and individualized instrument for forecasting the survival of SCLC with LM. Identifying the locations of synchronous extra LM and their corresponding prognoses can aid in guiding treatment decisions and optimizing treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.